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Abstract
Background: Research has shown that fecal biomarkers are useful to assess the activity of
inflammatory bowel disease (IBD). The aim of the study is: to evaluate the efficacy of the fecal
lactoferrin and calprotectin as indicators of inflammatory activity.
Findings: A total of 78 patients presenting inflammatory bowel disease were evaluated. Blood
tests, the Crohn's Disease Activity Index (CDAI), Mayo Disease Activity Index (MDAI), and
Crohn's Disease Endoscopic Index of Severity (CDEIS) were used for the clinical and endoscopic
evaluation. Two tests were performed on the fecal samples, to check the levels of calprotectin and
lactoferrin. The performance of these fecal markers for detection of inflammation with reference
to endoscopic and histological inflammatory activity was assessed and calculated sensitivity,
specificity, accuracy.
A total of 52 patient's samples whose histological evaluations showed inflammation, 49 were
lactoferrin-positive, and 40 were calprotectin-positive (p = 0.000). Lactoferrin and calprotectin
findings correlated with C-reactive protein in both the CD and UC groups (p = 0.006; p = 0.000),
with CDAI values (p = 0.043; 0.010), CDEIS values in DC cases (p = 0,000; 0.000), and with MDAI
values in UC cases (p = 0.000).
Conclusion:  Fecal lactoferrin and calprotectin are highly sensitive and specific markers for
detecting intestinal inflammation. Levels of fecal calprotectin have a proportional correlation to the
degree of inflammation of the intestinal mucosa.
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Findings
Inflammatory Bowel Disease (IBD) includes Crohn's Dis-
ease (CD) and Ulcerative Colitis (UC). These are chronic
idiopathic conditions, marked by recurrent episodes of
inflammation of the gastrointestinal tract, interspersed
with periods of remission. In order to determine the
degree of inflammatory activity, it is of the utmost impor-
tance to monitor patient's clinical evolution and adjust
their therapy [1].
Various indexes are used to evaluate the activity of the dis-
ease, which differ from each other in terms of being more
subjective (clinical), more objective (endoscopic-histo-
logical) or a combination of the two. However, despite the
different indexes available, there is not yet any consensus
in the literature as to which is the most valid. Laboratory
parameters such as C-reactive protein (CRP), erythrocyte
sedimentation rate (ESR), and hemoglobin, among oth-
ers, are not specific to active IBD, which makes it difficult
to use them routinely as markers of inflammatory activity
in clinical practice [2].
Some authors consider a colonoscopy with biopsy to be
the best means for evaluating inflammation location,
extent, and severity; aside from being an invasive method,
this approach carries risks of complications [3]. Various
studies have described fecal markers as powerful biomar-
kers of inflammation of the intestinal mucosa in patients
with IBD [3-8]. Fecal markers selected and studied as indi-
cators of inflammation include neutrophil granule pro-
teins, lactoferrin and calprotectin [2-8].
Lactoferrin is an iron-containing glycoprotein secreted by
the majority of mucosal membranes. It is the main com-
ponent of secondary polymorphonuclear granules, which
are the prime cells of an acute inflammatory response.
Other hematopoietic cells, such as monocytes and lym-
phocytes, do not contain lactoferrin. In intestinal inflam-
mation, leukocytes invade the mucosa, which results in an
increase in the excretion of lactoferrin into the feces [5,7].
Calprotectin is a calcium-containing protein that makes
up 5% of the total protein and 60% of the cytosolic pro-
tein of neutrophil. It has bacteriostatic and fungistatic
properties and is found in feces at levels six times higher
than that in plasma [[1,6], and [8]].
Several studies have compared fecal lactoferrin and cal-
protectin with activity indexes and/or endoscopic/histo-
logical evaluation to verify intestinal inflammation in IBD
patients. The results of these studies are promising, having
demonstrated that these markers are useful in detecting
inflammation and differentiating it from other diseases as
well as in predicting recurrence for periods of up to one
year [[1,2,5,8], and [9]]. Hence the present study sought
to evaluate the efficacy of fecal excretion biomarkers. Spe-
cifically, the first aim was to assess fecal lactoferrin and
calprotectin as indicators of IBD activity by determining
how well these indicators correlate with other indexes of
inflammatory activity including laboratory measures and
endoscopic and histological evaluation.
Patients and Methods
Patients
A total of 78 patients, 38 with CD and 40 with UC, were
recruited for this study, in accordance with the following
criteria for inclusion: (1) age 18 years or older; (2) written
informed consent given prior to participation such that
the terms were clear and free consent, as approved by the
Research Ethics Committee of the Central Hospital of the
Santa Casa of São Paulo; (3) being willing and available
to undertake all the procedures of the study, such as col-
lection of stool and blood samples and undergoing a
colonoscopy and/or double-balloon enteroscopy; and (4)
being able to come to the clinic where the study was tak-
ing place, whenever necessary. There were five exclusion
criteria as follows: (1) testing positive for HIV or Hepatitis
B or C; (2) history of infectious diarrhea during the previ-
ous six months; (3) infection with intestinal parasites; (4)
colostomy or ileostomy up to one month before study
enrollment; and (5) prior diagnosis with intestinal cancer.
Clinical data for the study's population are summarized in
Table 1.
Methods
The recruitment of patients
The patients were subjected to blood tests (hemoglobin,
hematocrit, leukocytes, platelets, CRP, ESR) and parasito-
logical tests on their feces. The patients selected were
advised that they should return to the clinic with two sam-
ples of fresh stool collected on the day of or, at most, 24
hours before their visit. In addition, they were asked about
Table 1: Summary of IBD patients' clinical data
Illness CD UC
Number of patients 38 40
Sex (male/female) 24/14 21/19
Median age (minimum-maximum) 37 (18-64) 46 (19-80)
Ethnicity (white, asian, mixed-race, black 32/0/5/1 33/1/3/3
Family history of IBD (yes/no) 4/34 6/34
Extent of disease
Terminal ileum 12
Ileum and colon 13
Pancolitis 11 12
Rectal + sigmoid + descending colon 3
Rectal 2 25
Surgery intended (Yes/no) 4/34 3/37
Treatment
Aminosalicylate 14 28
Immunosuppressant 16 11
Anti-TNF 8 1BMC Research Notes 2009, 2:221 http://www.biomedcentral.com/1756-0500/2/221
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their symptoms over the preceding seven days in the case
of patients with CD, and over the last three days in the
case of patients with UC, thereby allowing for the calcula-
tion of the Crohn's Disease Activity Index (CDAI) and the
Mayo Disease Activity Index (MDAI). CDAI and MDAI
values compatible with disease activity were > 150 points,
and > 0, respectively.
Fecal tests
During the study, patients' stool samples were subjected
to two tests: a quantitative one to determine the level of
calprotectin and a qualitative one to identify the presence
of lactoferrin. Quantitative measurement of calprotectin
was performed using PhiCal™ Test (Calpro AS, Oslo, Nor-
way). One to 5 g stool were collected and stored at -20°C.
Specimens were incubated with polyclonal rabbit anti-
bodies against calprotectin. Bound calprotectin was
allowed to reach with alkaline phosphatase labeled, imu-
noaffinity purified IgG (rabbit) antibodies against calpro-
tectin. After adding enzyme's substrate O.D. values were
read in an Elisa reader and compared to negative and pos-
itive kit controls. All steps were carried out following man-
ufactures' instructions.
Qualitative measurement of elevated levels of lactoferrin
was performed using IBD-CHEK test (Techlab, Blacks-
burg, VA, USA). One to 5 g stool were collected. Speci-
mens were incubated with immobilized polyclonal
antibody against lactoferrin and then detected with poly-
clonal antibody conjugated to horseradish peroxidase.
After substrate addition, colored enzyme-antibody-anti-
gen complexes formed in the presence of lactoferrin were
measured in an Elisa reader and compared to negative and
positive kit controls. All steps were carried out following
manufactures' instructions.
Endoscopic examinations
Patients with UC were given a colonoscopy, while those
with CD were given a double-balloon enteroscopy (was
performed through the rectum) to access inflammatory
activity. Two endoscopists (always the same ones) did all
of the analyses by video during the procedures without
knowledge of the results of the patients' blood tests or
fecal tests. Mayo Disease Activity Index (endoscopic sub
score), and Crohn's Disease Endoscopic Index of Severity
(values >/=3 were considered positive for intestinal
inflammation) were used for endoscopic evaluation.
Biopsies were performed each 10 cm in normal or patho-
logical areas of bowel.
Histological evaluation
The following data were assessed by histology: the pres-
ence of neutrophils in the lamina propria, the presence of
erosion and/or ulceration, and crypt aggression.
Statistical analysis
The statistical program SPSS (Statistical Package for Social
Sciences for Windows version 17.0) was used to analyze
the data, with the 5% level of significance (0.05). Spear-
man's Rank Correlation was applied to evaluate all the
variables studied, namely levels of hemoglobin, hemat-
ocrit, leukocytes, platelets, C-reactive protein, hemosedi-
mentation rates, fecal lactoferrin and calprotectin, CDAI,
MDAI, CDEIS, and histological evaluation. Sensitivity of
the variables was also studied in terms of their positive
predictive value, negative predictive value, and accuracy
relative to that of endoscopic and histological evaluation.
The best calprotectin cut-off point was calculated using
the area under the ROC (receiver operating characteristic)
curve.
Results
Fecal tests
Samples were lactoferrin-positive in 49 patients and lacto-
ferrin-negative in 29 patients (Table 2). Mean levels of
fecal calprotectin concentration were 686 mg/kg (ranging
from 52, 98 to 2542, 86 mg/Kg). The area under the ROC
curve to analyze the cut-off was 0,939 (Figure 1). The best
global cut-off was 200, 01 mg/Kg (sensitivity 88, 6; specif-
icity 97, 1). Calprotectin was present at levels above the
200 mg/kg in 40 patients whose biopsies showed intesti-
nal inflammation (Table 3). As the fecal calprotectin test
was quantitative, we chose to evaluate all levels of fecal
calprotectin found and to compare them to the degree of
inflammation as defined by the histological study of the
patients as a whole (Figure 2). All data were analyzed with
respect to sensitivity, specificity, positive predictive value,
Table 2: Comparison between fecal lactoferrin assessment and histological evaluation.
Histological evaluation
Fecal lactoferrin Crohn's Disease with 
Inflammation
Ulcerative Colitis with 
Inflammation
Crohn's Disease 
without Inflammation
Ulcerative Colitis 
without Inflammation
Total
Positive 22 (92%) 25 (89.3%) 2 (14.3%) 0 (0%) 49(62.8%)
Negative 2 (8%) 3 (10.7%) 12 (85.7%) 12 (100%) 29(37.2%)
Total 24 (100%) 28 (100%) 14 (100%) 12 (100%) 78 (100%)
p = 0.000 (Spearman rank correlation)BMC Research Notes 2009, 2:221 http://www.biomedcentral.com/1756-0500/2/221
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negative predictive value, and accuracy when compared to
endoscopic (Table 4) and histological evaluation (Table
5).
Correlation between fecal markers, clinical activity index 
(CDAI), endoscopy (CDEIS) and clinical-endoscopy 
(MDAI)
In patients with CD, lactoferrina and calprotectin results
were found to correlate with CDAI (p = 0,043; p = 0,010,
respectively) and the CDEIS results (p = 0.000; p = 0.000,
respectively). In patients with UC, lactoferrina and calpro-
tectin correlated with MDAI results (p = 0.000; p = 0,000;
respectively).
Correlation between fecal markers and blood tests (C-
reactive protein)
Lactoferrin and calprotectin findings correlated only with
C-reactive protein findings in both the CD and UC groups
(p = 0.006; p = 0.000).
Discussion
Inflammation is the basis for many signs and symptoms
of disease, making its detection and monitoring funda-
mental to clinical management. At present, a majority of
studies have shown that the best way to assess inflamma-
tion is through endoscopic and/or histological evaluation
[[1,8], and [9]]. Patients' symptoms can be indicators of
inflammation and disease activity, but these are subjective
and are often influenced by disease factors that are not
inflammatory (fibrosis). Various clinical indices devel-
oped to calculate inflammatory activity among patients
with IBD rely on the combination of signs and symptoms
[1].
One means to assess inflammation that has been dis-
cussed in recent years is the analysis of the infiltration of
neutrophil in the intestinal mucosa and their transmigra-
tion to the lumen [10]. When intestinal inflammation
occurs, fecal lactoferrin rises rapidly and correlates with
endoscopic and histological alterations in patients with
IBD, supporting the idea that it is a sensitive and specific
means to identity inflammatory activity in these patients
[7].
Several authors working on the role of fecal lactoferrin in
IBD patients have shown that concentrations of lactofer-
rin are significantly higher in patients with active disease
than in those with inactive disease [7]. These results are
consistent with those found in the current study, in which
we found that samples from 49 out of 52 patients with
intestinal inflammation detected by histological evalua-
tion were positive for lactoferrin.
Another marker derived from neutrophil that has shown
great promise for identifying intestinal inflammation is
fecal calprotectin [1,11-17]. In patients with active IBD,
calprotectin values vary between 200 mg/kg and 20,000
mg/kg [4,18-21].
Many authors have claimed that calprotectin levels corre-
late closely with histological evaluation than macroscopic
findings, suggesting that this biological marker is more
sensible than endoscopy in evaluating IBDs activity [4,8].
Furthermore fecal calprotectin concentrations predicted
the severity of colorectal inflammation, with advanced
histological grades of colorectal inflammation [4]. In our
study has demonstrated that more intense levels of
inflammation are associated with elevated calprotectin
values, demonstrating a significant correlation between
calprotectin and the severity of inflammation. However
the accuracy of calprotectin predicted inflammation when
compared with endoscopic and histological were 92, 3%
and 85%.
Calprotectin determination appears to better reflect dis-
ease activity in UC than CD [21,22]. As an example, Costa
et al. found that fecal calprotectin levels above 50 ug/g
were better correlated with the colitis activity index than
the CDAI [21]. The relatively poor correlation between
calprotectin levels and CDAI might indeed not be due to
a calprotectin pitfall, but to the fact that CDAI is mostly a
clinical score and is not sensitive enough to detect subclin-
ical activity of the disease, which is known to occur rather
frequently in CD. Nevertheless, several studies could not
demonstrate a correlation between fecal calprotectin and
Area under the receiver operating characteristic (ROC)  curve to analyze the best cut off of calprotectin Figure 1
Area under the receiver operating characteristic 
(ROC) curve to analyze the best cut off of calprotec-
tin.BMC Research Notes 2009, 2:221 http://www.biomedcentral.com/1756-0500/2/221
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clinical activity of CD (evaluated by CDAI) [23,24] or
endoscopic lesions (evaluated by CDEIS) [24].
Sipponen et al. found that both fecal Calprotectin and
lactoferrin correlated significantly with CDEIS (Spear-
man's r 0,729, p < 0,001). With a cut-off level of 200
microg/g for a raised fecal Calprotectin concentration,
sensitivity was 70%, specificity 92% in predicting endo-
scopically active disease [25].
Other studies have not been able to demonstrate correla-
tion between fecal calprotectin concentration and UCs
clinical activity [6]. It has been suggested, but not proved;
that CD patients' stratification based on phenotypical pat-
tern (inflammatory, stricturing or fistulizing) could
improve calprotectin's predictive capacity for this disease.
As calprotectin is an inflammation marker, its predictive
role will probably produce best results in the inflamma-
tory pattern of the disease [26]. In summary, the exact
strength of any correlation of fecal calprotectin levels with
disease activity indicators is therefore not well established
at present [27].
In patients with Colitis, it was observed that all patients
with clinical and endoscopic signs of inflammation (as
determined by the MDAI) had lactoferrin and calprotectin
presents in their stool. These findings also occurred in
patients with CD; however there were few patients with
CDAI higher than 150 points, so further studies are
required to resolve this issue.
Both lactoferrin and calprotectin were present in the
majority of samples from patients with elevated CRP, but
we didn't find a good correlation with fecal markers and
Table 3: Comparison between fecal calprotectin and histological evaluation.
Histological evaluation
Fecal calprotectin Crohn's Disease with 
Inflammation
Ulcerative Colitis 
with Inflammation
Crohn's Disease 
without 
Inflammation
Ulcerative Colitis 
without 
Inflammation
Total
Positive (>200 ng/ml) 20 (83.3%) 20 (71.4%) 0 (0%) 0 (0%) 40(51.3%)
Negative 4 (16.7%) 8 (28.6%) 14 (100%) 12 (100%) 38 (48.7%)
Total 24 (100%) 28 (100%) 14 (100%) 12 (100%) 78 (100%)
p = 0.000 (Spearman rank correlation)
Comparison between fecal Calprotectin and intensity of histological inflammation Figure 2
Comparison between fecal Calprotectin and intensity of histological inflammation. P=0.000 (Spearman Rank Cor-
relation). Histological Evaluation (degree of inflammation):  0: absent, 1: slight, 2: moderate, 3: severe.BMC Research Notes 2009, 2:221 http://www.biomedcentral.com/1756-0500/2/221
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others laboratory parameters. Hemoglobin, hematocrit,
leukocytes, platelets and ESR are routinely used as inflam-
matory markers in blood when IBD is suspected. How-
ever, these markers correlate poorly with endoscopic and
histological [9], as we also found.
Conclusion
Several conclusions can be made from the present results.
Firstly, fecal lactoferrin and calprotectin are sensitive and
specific markers for the detection of intestinal inflamma-
tion in IBD patients. Secondly, fecal calprotectin levels are
directly proportional to the degree of inflammation in the
intestinal mucosa.
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